Microbot’s LIBERTY Pivotal Trial Completes Enrollment of Clinical Sites

July 26, 2024—Microbot Medical Inc. recently announced it has received institutional review board approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center in New York, New York, to conduct a clinical trial under an investigational device exemption for its Liberty endovascular robotic surgical system. The company expects the trial results will support the future marketing submission to the FDA and subsequent commercialization of the Liberty system.

The company advised that Francois Cornelis, MD, will lead the clinical trial at Memorial Sloan Kettering and will also serve as principal investigator for the overall LIBERTY clinical trial.

“I’m a great believer in the future of robotics for interventional procedures and the value robotics can bring to physicians and our patients,” commented Dr. Cornelis in the company’s press release. “I am excited to participate in the LIBERTY clinical trial.”

Memorial Sloan Kettering Cancer Center is the third and final clinical site for the pivotal clinical trial. The company announced on June 20 and July 16, respectively, that Brigham and Women’s Hospital in Boston, Massachusetts, and Baptist Hospital of Miami in Miami, Florida, were enrolled as the first two clinical sites in the trial. Both sites have performed clinical cases, stated Microbot.